Chile Gastric Cancer Treatment Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF CHILE GASTRIC CANCER TREATMENT MARKET 11
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 16
2.4 CURRENCY AND PRICING 16
2.5 DBMR TRIPOD DATA VALIDATION MODEL 17
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
2.7 MULTIVARIATE MODELLING 21
2.8 TYPE LIFELINE CURVE 21
2.9 DBMR MARKET POSITION GRID 22
2.10 VENDOR SHARE ANALYSIS 23
2.11 MARKET END USER COVERAGE GRID 23
2.12 SECONDARY SOURCES 25
2.13 ASSUMPTIONS 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 29
4.1 PESTEL'S MODEL 30
4.2 PORTER'S 5 FORCES 31
5 EPIDEMIOLOGY 32
6 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET 33
7 SUMMARY WRITE-UP, CHILE 35
7.1 OVERVIEW 35
8 CHILE GASTRIC CANCER TREATMENT MARKET: REGULATORY SCENARIO 36
9 MARKET OVERVIEW 38
9.1 DRIVERS 40
9.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA 40
9.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 40
9.1.3 HEALTH SYSTEM OF CHILE 41
9.1.4 HIGH PREVALENCE OF OBESITY 41
9.1.5 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT 42
9.2 RESTRAINTS 42
9.2.1 COMMERCIALIZATION OF PHARMACEUTICALS IN CHILE 42
9.2.2 HIGH COST OF TESTING AND MEDICATIONS 43
9.2.3 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT 44
9.3 OPPORTUNITIES 45
9.3.1 INCREASING DRUG APPROVALS 45
9.3.2 GOVERNMENT INITIATIVES FOR CANCER CARE 45
9.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 46
9.4 CHALLENGES 46
9.4.1 CHALLENGE RELATED TO HEALTHCARE PROFESSIONALS 46
9.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES 47
10 IMPACT OF COVID-19 PANDEMIC ON CHILE GASTRIC CANCER TREATMENT MARKET 48
10.1 PRICE IMPACT 48
10.2 IMPACT ON DEMAND 48
10.3 IMPACT ON SUPPLY CHAIN 49
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS 49
10.5 CONCLUSION 49
11 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE 50
11.1 OVERVIEW 51
11.2 ADENOCARCINOMA 53
11.3 GASTROINTESTINAL STROMAL TUMOR 54
11.4 CARCINOID TUMOR 54
11.5 LYMPHOMA 55
11.6 OTHERS 55
12 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES 56
12.1 OVERVIEW 57
12.2 STAGE III 60
12.3 STAGE II 60
12.4 STAGE IV 60
12.5 STAGE I 61
12.6 OTHERS 61
13 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT 62
13.1 OVERVIEW 63
13.2 CHEMOTHERAPY 66
13.2.1 FLUOROURACIL 67
13.2.2 OXALIPLATIN 67
13.2.3 CISPLATIN 67
13.2.4 DOCETAXEL 67
13.2.5 PACLITAXEL 67
13.2.6 IRINOTECAN 67
13.2.7 CAPECITABINE 67
13.2.8 CARBOPLATIN 67
13.2.9 EPIRUBICIN 67
13.2.10 OTHERS 67
13.3 TARGETED THERAPY 68
13.3.1 MONOCLONAL ANTIBODY THERAPY 68
13.3.1.1 trastuzumab (herceptin) 68
13.3.1.2 ramucirumab 68
13.3.2 MULTIKINASE INHIBITORS 69
13.3.2.1 Sunitinib 69
13.3.2.2 Regorafenib 69
13.4 IMMUNE CHECKPOINT INHIBITORS 69
13.5 OTHERS 69
14 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 70
14.1 OVERVIEW 71
14.2 PARENTERAL 74
14.2.1 INTRAVENOUS 74
14.2.2 SUBCUTANEOUS 74
14.2.3 OTHERS 74
14.3 ORAL 75
14.3.1 TABLET 75
14.3.2 CAPSULE 75
14.3.3 OTHERS 75
14.4 OTHERS 76
15 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS 77
15.1 OVERVIEW 78
15.2 HOSPITALS 80
15.3 SPECIALITY CLINICS 81
15.4 RESEARCH & ACADEMIC INSTITUTES 81
15.5 OTHERS 81
16 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 82
16.1 OVERVIEW 83
16.2 HOSPITAL PHARMACY 86
16.3 RETAIL PHARMACY 86
16.4 OTHERS 87
17 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE 88
17.1 COMPANY SHARE ANALYSIS: CHILE GASTRIC CANCER TREATMENT MARKET 88
18 SWOT ANALYSIS 89
19 COMPANY PROFILE 90
19.1 MERCK KGAA 90
19.1.1 COMPANY SNAPSHOT 90
19.1.2 REVENUE ANALYSIS 90
19.1.3 PRODUCT PORTFOLIO 91
19.1.4 RECENT DEVELOPMENTS 91
19.2 F.HOFFMAN-LA ROCHE LTD 92
19.2.1 COMPANY SNAPSHOT 92
19.2.2 REVENUE ANALYSIS 92
19.2.3 PRODUCT PORTFOLIO 93
19.2.4 RECENT DEVELOPMENT 93
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 94
19.3.1 COMPANY SNAPSHOT 94
19.3.2 REVENUE ANALYSIS 94
19.3.3 PRODUCT PORTFOLIO 95
19.3.4 RECENT DEVELOPMENT 95
19.4 ASTRAZENECA 96
19.4.1 COMPANY SNAPSHOT 96
19.4.2 REVENUE ANALYSIS 96
19.4.3 PRODUCT PORTFOLIO 97
19.4.4 RECENT DEVELOPMENTS 97
19.5 SANOFI 98
19.5.1 COMPANY SNAPSHOT 98
19.5.2 REVENUE ANALYSIS 98
19.5.3 PRODUCT PORTFOLIO 99
19.5.4 RECENT DEVELOPMENTS 99
19.6 MEGALABS CHILE S.A. 100
19.6.1 COMPANY SNAPSHOT 100
19.6.2 PRODUCT PORTFOLIO 100
19.6.3 RECENT DEVELOPMENT 100
19.7 BRISTOL-MYERS SQUIBB COMPANY 101
19.7.1 COMPANY SNAPSHOT 101
19.7.2 REVENUE ANALYSIS 101
19.7.3 PRODUCT PORTFOLIO 102
19.7.4 RECENT DEVELOPMENTS 102
19.8 CELNOVA PHARMA 103
19.8.1 COMPANY SNAPSHOT 103
19.8.2 PRODUCT PORTFOLIO 103
19.8.3 RECENT DEVELOPMENT 103
19.9 GRUPO BIOTOSCANA 104
19.9.1 COMPANY SNAPSHOT 104
19.9.2 REVENUE ANALYSIS 104
19.9.3 PRODUCT PORTFOLIO 105
19.9.4 RECENT DEVELOPMENT 105
19.10 LABORATORI VARIFARMA S.A. 106
19.10.1 COMPANY SNAPSHOT 106
19.10.2 PRODUCT PORTFOLIO 106
19.10.3 RECENT DEVELOPMENT 106
19.11 NOVARTIS AG 107
19.11.1 COMPANY SNAPSHOT 107
19.11.2 REVENUE ANALYSIS 107
19.11.3 PRODUCT PORTFOLIO 108
19.11.4 RECENT DEVELOPMENT 108
19.12 PFIZER INC. 109
19.12.1 COMPANY SNAPSHOT 109
19.12.2 REVENUE ANALYSIS 109
19.12.3 PRODUCT PORTFOLIO 110
19.12.4 RECENT DEVELOPMENTS 110
19.13 TECNOFARMA S.A. 111
19.13.1 COMPANY SNAPSHOT 111
19.13.2 PRODUCT PORTFOLIO 111
19.13.3 RECENT DEVELOPMENT 111
20 QUESTIONNAIRE 112
21 RELATED REPORTS 115